“South Africa’s Department of Health has launched its 2026–2027 Annual Performance Plan, allocating R64.8 billion to strengthen hospital infrastructure, expand HIV prevention through lenacapavir injections, and intensify HPV vaccination and screening. The plan aims to eliminate cervical cancer by 2030 and significantly reduce HIV transmission rates, positioning South Africa as a global leader in healthcare reform.”
South Africa has entered a transformative era in healthcare with the unveiling of its 2026–2027 Annual Performance Plan (APP). The government’s commitment of R64.8 billion marks one of the most ambitious health reforms in the nation’s history. This plan addresses three critical areas: hospital infrastructure modernization, HIV prevention through innovative long-acting injections, and cervical cancer elimination via expanded HPV vaccination and screening. Together, these initiatives aim to reshape the country’s public health landscape and position South Africa as a global leader in healthcare reform.
Hospital Infrastructure Reform
A significant portion of the APP funding is dedicated to modernizing hospitals and district facilities across provinces such as Limpopo, Free State, Eastern Cape, and Mpumalanga.
Key goals include:
- Reducing overcrowding in hospitals.
- Replacing outdated equipment to improve service delivery.
- Expanding hospital capacity to support the rollout of National Health Insurance (NHI).
Already, 11 bids worth over R1 billion have been submitted under the Budget Facility for Infrastructure. This infrastructure push is not merely about construction but about equitable access to quality healthcare. By modernizing facilities, the government aims to ensure resilience, efficiency, and fairness in healthcare delivery.
HIV Prevention: Lenacapavir Rollout
One of the most groundbreaking aspects of the plan is the rollout of lenacapavir injections, a long-acting antiretroviral that provides protection for six months. Unlike daily oral PrEP, lenacapavir offers a more convenient and effective solution.
- Target groups: Young people, rural communities, and marginalized populations.
- Impact: Expected to significantly reduce HIV transmission rates in one of the world’s highest-burden countries.
- Public acceptance: Early rollout data shows 98.5% of HIV-negative people offered a choice between daily pills and lenacapavir chose the injection.
Health Minister Aaron Motsoaledi emphasized that South Africa is now positioned to “eliminate HIV/AIDS as a public health threat.” This bold statement reflects the government’s confidence in the effectiveness of lenacapavir and its potential to change the trajectory of the HIV epidemic.
Cervical Cancer Elimination Strategy
Another cornerstone of the plan is the elimination of cervical cancer by 2030, targeting an incidence of fewer than 4 cases per 100,000 women.
The strategy aligns with the World Health Organization’s 90-70-90 targets:
- 90% HPV vaccination coverage for girls under 15.
- 70% screening coverage using high-performance tests.
- 90% treatment coverage for identified cases.
South Africa is intensifying HPV vaccination campaigns and expanding screening programs, particularly in underserved areas. This dual approach ensures that prevention and treatment are accessible to all women, regardless of socioeconomic status.
olicy Significance
This APP is not just a health plan—it is a policy milestone. By aligning infrastructure development with National Infrastructure Plan 2050, the government ensures that healthcare facilities are financially sustainable and capable of meeting long-term needs.
The reforms also strengthen the foundation for universal health coverage, a goal South Africa has been pursuing for decades. The integration of innovative HIV prevention and cancer elimination strategies demonstrates a forward-looking approach that blends medical science with public health policy.
Challenges and Criticisms
Despite the optimism, challenges remain. Critics argue that the Department of Health’s procurement policies have undermined the local pharmaceutical industry by prioritizing cheaper imports over locally produced medicines. This has led to 2,500 job losses in the past 18 months and raised concerns about the country’s ability to respond to future pandemics.
Balancing cost efficiency with industrial policy goals will be crucial. Without strong local manufacturing capacity, South Africa risks dependency on external suppliers during health crises.
Conclusion
South Africa’s R64.8 billion healthcare reform plan represents a bold step toward a healthier future. By modernizing infrastructure, rolling out lenacapavir injections, and intensifying HPV vaccination and screening, the country is tackling its most pressing health challenges head-on.
If successful, this plan will not only reduce HIV transmission and eliminate cervical cancer but also transform the healthcare system into a model of equity and resilience. The coming years will test the government’s ability to deliver on these promises, but the vision is clear: a healthier, stronger South Africa.
